🏛️ Verified NIH Record • Updated 2026-08-20

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP (NCT07091630)

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: argenx

🩺 Plain-English Summary (8th-Grade Level)

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emnergize

Who can join: Review the eligibility criteria below.

Location: University of Alabama at Birmingham - 1720 University Blvd — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (78 Sites)

Showing the first 25 of 78 sites.

  • University of Alabama at Birmingham - 1720 University Blvd — Birmingham, Alabama
  • Samir Macwan, M.D., Inc. (S corporation) — Rancho Mirage, California
  • Colorado Springs Neurological Associates — Colorado Springs, Colorado
  • Medstar Health Research Institute — Washington D.C., District of Columbia
  • Gables Neurology — Miami, Florida
  • Aqualane Clinical Research — Naples, Florida
  • Paradigm Health System — Slidell, Louisiana
  • Penn Medicine University City — Philadelphia, Pennsylvania
  • Jefferson Health Honickman Center — Philadelphia, Pennsylvania
  • National Neuromuscular Research Institute — Austin, Texas
  • NeuroCarePlus — Houston, Texas
  • Instituto Privado Kremer — Córdoba,
  • Instituto Médico de la Fundación Estudios Clínicos — Rosario,
  • INECO Neurociencias Oroño — Rosario,
  • Kepler Universitätsklinikum Linz - Med Campus III — Linz, Upper Austria
  • Universitätsklinikum AKH Wien — Vienna,
  • L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME — Brasília,
  • Hospital Moinhos de Vento — Porto Alegre,
  • PSEG Centro de Pesquisa Clinica — São Paulo,
  • Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv. Naum EAD — Sofia, Sofia
  • University Multiprofile Hospital for Active Treatment — Pleven,
  • Medical Center Medika 2005 - Branch Sofia — Sofia,
  • University Multiprofile Hospital for Active Treatment Aleksandrovska EAD — Sofia,
  • University Multiprofile Hospital for Active Treatment and Emergency Medicine N. I. Pirogov EAD — Sofia,
  • Fujian Medical University Union Hospital - Yushan Campus — Fuzhou, Fujian

📞 Contact the Study Coordinator

Phone: (857) 350-4834

Email: clinicaltrials@argenx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Inflammatory Demyelinating Polyneuropathy

Explore by condition: All Chronic Inflammatory Demyelinating Polyneuropathy clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗